Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 | Q13639 | 16/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.83 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.32 |
| ▸ | DHFR | P00374 | 1/20 | 0.32 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pf-04995274 SCHEMBL619629 | 1.00 | HTR4 (1.00) | HTR4CYP3A4ACHEKCNH2MCHR1 | |
| Pf-04995274 SCHEMBL619630 | 1.00 | HTR4 (1.00) | HTR4CYP3A4ACHEKCNH2MCHR1 | |
| SCHEMBL2331352 | 0.96 | HTR4 (1.00) | HTR4CYP3A4ACHEKCNH2DHFR | |
| SCHEMBL14138520 | 0.91 | HTR4 (0.90) | HTR4CYP3A4ACHEKCNH2 | |
| SCHEMBL2333665 | 0.90 | HTR4 (0.92) | HTR4CYP3A4ACHEKCNH2 | |
| SCHEMBL2333671 | 0.90 | HTR4 (0.92) | HTR4CYP3A4ACHEKCNH2 | |
| SCHEMBL2335982 | 0.89 | HTR4 (1.00) | HTR4CYP3A4ACHEKCNH2 | |
| SCHEMBL5116742 | 0.89 | HTR4 (1.00) | HTR4CYP3A4ACHEKCNH2 | |
| SCHEMBL2332439 | 0.85 | HTR4 (0.78) | HTR4CYP3A4ACHEKCNH2 | |
| SCHEMBL5117176 | 0.85 | HTR4 (0.78) | HTR4CYP3A4ACHEKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250213564-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND OTHER NEUROGENERATIVE DISEASE | THE RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC. | 2025-07-03 | — | — | US | claimed |
| EP-4577305-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND OTHER NEUROGENERATIVE DISEASE | 1/1THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2025-07-02 | — | — | EP | claimed |
| WO-2024044355-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND OTHER NEUROGENERATIVE DISEASE | 1/1THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2024-02-29 | — | — | WO | claimed |
| US-20230121608-A1 | Compositions and Methods for the Prevention of Stress-Induced Fear, Depressive-Like and Anxiety- Like Behavior | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-04-20 | — | — | US | claimed |
| CN-115916174-A | Compositions and methods for preventing stress-induced phobia, depression-like, and anxiety-like behaviors | 纽约市哥伦比亚大学理事会 | 2023-04-04 | — | — | CN | claimed |
| EP-4132496-A1 | COMPOSITIONS AND METHODS FOR THE PREVENTION OF STRESS-INDUCED FEAR, DEPRESSIVE-LIKE AND ANXIETY- LIKE BEHAVIOR | The Trustees of Columbia University in the City of New York (US) | 2023-02-15 | — | — | EP | claimed |
| US-20220031684-A1 | PROPHYLACTIC EFFICACY OF SEROTONIN 4 RECEPTOR AGONISTS AGAINST STRESS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2022-02-03 | — | — | US | claimed |
| US-20250213564-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND OTHER NEUROGENERATIVE DISEASE | THE RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC. | 2025-07-03 | — | — | US | disclosed |
| EP-4577305-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND OTHER NEUROGENERATIVE DISEASE | 1/1THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2025-07-02 | — | — | EP | disclosed |
| WO-2024044355-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND OTHER NEUROGENERATIVE DISEASE | 1/1THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2024-02-29 | — | — | WO | disclosed |
| EP-3870261-B1 | INGESTIBLE DEVICE FOR DELIVERY OF THERAPEUTIC AGENT TO THE GASTROINTESTINAL TRACT | BIORA THERAPEUTICS INC (US) | 2024-01-31 | — | — | EP | disclosed |
| EP-4309722-A2 | INGESTIBLE DEVICE FOR DELIVERY OF THERAPEUTIC AGENT TO THE GASTROINTESTINAL TRACT | Biora Therapeutics, Inc. (US) | 2024-01-24 | — | — | EP | disclosed |
| US-11707610-B2 | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract | BIORA THERAPEUTICS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| EP-3592741-B1 | NOVEL IMIDAZO[4,5-C]QUINOLINE DERIVATIVES AS LRRK2 INHIBITORS | PFIZER (US) | 2023-02-15 | — | — | EP | disclosed |
| CN-115666704-A | Ingestible device for delivery of therapeutic agents to the gastrointestinal tract | 比奥拉治疗股份有限公司 | 2023-01-31 | — | — | CN | disclosed |
| CN-111051304-B | Imidazo [4,5-c ] quinoline derivatives as LRRK2 inhibitors | 辉瑞大药厂 | 2022-12-27 | — | — | CN | disclosed |
| US-11453701-B2 | Tau aggregation peptide inhibitors | ADRX, INC. (US) | 2022-09-27 | — | — | US | disclosed |
| CN-111201226-B | Cyclic substituted imidazo [4,5-c ] quinoline derivatives | 辉瑞大药厂 | 2022-07-22 | — | — | CN | disclosed |
| US-11312713-B2 | Imidazo[4,5-C]quinoline derivatives as LRRK2 inhibitors | PFIZER INC. (US) | 2022-04-26 | — | — | US | disclosed |
| US-20220031684-A1 | PROPHYLACTIC EFFICACY OF SEROTONIN 4 RECEPTOR AGONISTS AGAINST STRESS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2022-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11707610-B2 | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract | MUC1, SLC10A2, FABP2 | HTR4 2179/4885CYP3A4 4413/4885ACHE 921/4885 |
| US-11312713-B2 | Imidazo[4,5-C]quinoline derivatives as LRRK2 inhibitors | LRRK2, PARK7, BRCA1 | HTR4 2582/4885CYP3A4 2187/4885ACHE 257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.